bpc-157 human clinical trials safety fda status advisory committee votes to add popular peptide to drug compounding list FDA's Overreach on Compounded Peptides

FDA's Overreach on Compounded Peptides An FDA advisory committee voted Thursday to remove compounding restrictions on four peptides despite little evidence the products are safe or effective for medical use. In a series of 8 6 votes (with FDA advisers back first four of seven unapproved peptides under review for looser rules Reuters 3 FOR 3. An FDA advisory committee has now voted 86, with one abstention, to recommend BPC 157, KPV and TB 500 for inclusion on the 503A Bulks List. This is not FDA approval

SKU: 71810855764 · From infinitumclavis.com.tr